News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Positive Clinical Data for TASQ - Active Biotech AB’s Novel Treatment of Prostate Cancer
March 9, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN -- (MARKET WIRE) -- March 09, 2007 -- Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Europe
MORE ON THIS TOPIC
Drug Development
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart
October 8, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
October 8, 2026
·
2 min read
·
Gabrielle Masson
Weight loss
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
October 8, 2026
·
4 min read
·
Annalee Armstrong
Insights
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026
·
1 min read
·
Jennifer C. Smith-Parker
